- Home
- CRIS vs LPCN Comparison
CRIS vs LPCN Comparison
Compare CRIS & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRIS
- LPCN
- Stock Information
- Founded
- CRIS 2000
- LPCN 1997
- Country
- CRIS United States
- LPCN United States
- Employees
- CRIS 33
- LPCN N/A
- Industry
- CRIS Biotechnology: Biological Products (No Diagnostic Substances)
- LPCN Biotechnology: Pharmaceutical Preparations
- Sector
- CRIS Health Care
- LPCN Health Care
- Exchange
- CRIS Nasdaq
- LPCN Nasdaq
- Market Cap
- CRIS 13.5M
- LPCN 16.1M
- IPO Year
- CRIS 2000
- LPCN N/A
- Fundamental
- Price
- CRIS $1.50
- LPCN $3.10
- Analyst Decision
- CRIS Strong Buy
- LPCN Strong Buy
- Analyst Count
- CRIS 3
- LPCN 1
- Target Price
- CRIS $21.00
- LPCN $10.00
- AVG Volume (30 Days)
- CRIS 102.7K
- LPCN 10.3K
- Earning Date
- CRIS 05-06-2025
- LPCN 05-08-2025
- Dividend Yield
- CRIS N/A
- LPCN N/A
- EPS Growth
- CRIS N/A
- LPCN N/A
- EPS
- CRIS N/A
- LPCN N/A
- Revenue
- CRIS $10,908,000.00
- LPCN $11,198,144.00
- Revenue This Year
- CRIS $2.33
- LPCN N/A
- Revenue Next Year
- CRIS $9.78
- LPCN N/A
- P/E Ratio
- CRIS N/A
- LPCN N/A
- Revenue Growth
- CRIS 8.83
- LPCN N/A
- 52 Week Low
- CRIS $1.02
- LPCN $2.75
- 52 Week High
- CRIS $16.99
- LPCN $11.79
- Technical
- Relative Strength Index (RSI)
- CRIS 37.70
- LPCN 46.56
- Support Level
- CRIS $1.06
- LPCN $2.82
- Resistance Level
- CRIS $1.30
- LPCN $3.27
- Average True Range (ATR)
- CRIS 0.15
- LPCN 0.23
- MACD
- CRIS 0.07
- LPCN 0.01
- Stochastic Oscillator
- CRIS 70.59
- LPCN 58.92
About CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.